CapsoVision (CV) Research & Development (2024 - 2025)
CapsoVision's (CV) quarterly Research & Development came in at $2.4 million in Q4 2025, down 22.98% year-on-year from $3.1 million in Q4 2024, and down 60.59% quarter-over-quarter from $6.1 million in Q3 2025.
CapsoVision (CV) Research & Development (2024 - 2025) Analysis & Trends
CapsoVision has disclosed Research & Development across 2 years of filings, most recently posting $2.4 million for Q4 2025.
- Research & Development for Q4 2025 came in at $2.4 million, down 22.98% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.0 million (changed N/A YoY), and the FY2025 annual result was $18.3 million, up 21.1% from the prior year.
- Research & Development came in at $2.4 million for Q4 2025 at CapsoVision, down from $6.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.1 million in Q3 2025 to a low of $2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 767.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 413.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 722.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 516.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 263.30 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -461.27 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 145.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 345.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 28.80 Mn |
| 10 | CapsoVision | 161.82 Mn | 151.71 Mn | 1.95 Mn | 2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 6.09 Mn |
| Jun 30, 2025 | 3.39 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 4.22 Mn |